5. Progressive supranuclear palsy Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 89 Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

Drugs and their primary sponsors and trial info
18F-AV-1451   
   Skåne University Hospital, Region Skåne
      2014   -   EUCTR2014-000422-38-SE   Sweden;
18F-FDG   
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan;
18F-RO6958948   
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione   
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom;
9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER   
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia;
AB1010   
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain;
ABBV-8E12   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2018   Phase 2   EUCTR2017-001590-16-IT   Australia;Canada;Germany;Italy;United States;
      2017   Phase 2   EUCTR2016-001635-12-IT   Australia;Canada;Italy;United States;
   AbbVie
      2018   Phase 2   NCT03391765   Australia;Canada;France;Italy;Japan;United States;
      2018   Phase 1   NCT03413319   United States;
      2016   Phase 2   NCT02985879   Australia;Canada;France;Germany;Italy;Japan;Spain;United States;
   AbbVie Deutschland
      2019   Phase 2   EUCTR2017-001590-16-DE   Australia;Canada;Germany;United States;
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 2   EUCTR2016-001635-12-ES   Australia;Canada;Germany;Italy;Spain;United States;
      2017   Phase 2   EUCTR2016-001635-12-FR   Australia;Canada;France;Germany;Italy;Spain;United States;
      2017   Phase 2   EUCTR2016-001635-12-DE   Australia;Canada;Germany;Italy;Spain;United States;
AL-108   
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States;
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States;
ASK Nr. 21972   
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
AZP2006 oral solution   
   AlzProtect SAS
      2020   Phase 2   NCT04008355   France;
Alpha-lipoic acid and L-acetyl carnitine   
   Weill Medical College of Cornell University
      2010   Phase 1/Phase 2   NCT01537549   United States;
Anti-Parkinson medication   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Antisense oligonucleotide   
   Novartis Pharmaceuticals
      2021   Phase 1   NCT04539041   Canada;Germany;United Kingdom;United States;
Apomorphine   
   Fondation Ophtalmologique Adolphe de Rothschild
      2018   -   NCT04786158   France;
Azilect   
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
BIIB092   
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-002554-21-IT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   Biogen
      2017   Phase 2   NCT03068468   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 1   NCT02658916   United States;
      2015   Phase 1   NCT02460094   United States;
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-002554-21-GR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-GB   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-DE   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002554-21-AT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
BMS-986168   
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   Bristol-Myers Squibb K.K.
      2017   Phase 2   JPRN-JapicCTI-173627   -
BMS986168   
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Bepranemab   
   UCB Biopharma SRL
      2019   Phase 1   NCT04185415   Belgium;Germany;Spain;United Kingdom;
Brain PET scan   
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
CoQ10   
   Lahey Clinic
      2004   Phase 2/Phase 3   NCT00532571   United States;
Coenzym Q10 Nanodispersion   
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Coenzym Q10, Ubiquinon, Ubichinon   
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Coenzyme Q10   
   German Parkinson Study Group (GPS)
      2006   Phase 2   NCT00328874   Germany;
   Lahey Clinic
      2006   -   NCT00382824   United States;
DaTSCAN™ Ioflupane (123I) Injection   
   GE Healthcare
      2020   Phase 3   NCT04193527   China;
Davunetide   
   Allon Therapeutics
      2010   Phase 2/Phase 3   NCT01110720   Australia;Canada;France;Germany;United Kingdom;United States;
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States;
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States;
Davunetide (AL-108, NAP)   
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States;
Deep Brain Stimulation   
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Donepezil   
   Groupe Hospitalier Pitie-Salpetriere
      2005   Phase 2   NCT00139373   France;
Droxidopa   
   Loma Linda University
      2021   Phase 2   NCT03446807   United States;
Emeramide   
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
Example   
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2000041207   China;
Exelon 1,5 mg Hartkapseln   
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
Exelon 3,0 mg Hartkapseln   
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
Exelon 6,0 mg Hartkapseln   
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany;
F-18   
   Chang Gung Memorial Hospital
      2018   Early Phase 1   NCT03625128   Taiwan;
F-18 AV 1451   
   Mayo Clinic
      2015   -   NCT02605785   United States;
Fasudil   
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT04734379   United States;
Flortaucipir F18   
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States;
Flutemetamol   
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   Japan;
Flutemetamol F18   
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Fresh Frozen Plasma   
   University of California, San Francisco
      2015   Phase 1   NCT02460731   United States;
GDNF & Synchro Med Infusion System   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00005903   United States;
Gold   
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2000041207   China;
      2019   Phase 0   ChiCTR2000030512   China;
Hydrogen   
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Leucine   
   Washington University School of Medicine
      2017   -   NCT03545126   United States;
Lithium   
   Westat
      2008   Phase 1/Phase 2   NCT00703677   United Kingdom;United States;
N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE   
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NBMI   
   EmeraMed
      2019   Phase 2   NCT04184063   Slovenia;
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NP031112   
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom;
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom;
NT 101   
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Nitrogen   
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Placebo   
   Bristol-Myers Squibb K.K.
      2017   Phase 2   JPRN-JapicCTI-173627   -
Pyruvate, creatine, niacinamide   
   University of Louisville
      2004   -   NCT00605930   United States;
RASAGILINE MESILATE   
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
RT001   
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia;
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia;
   Retrotope, Inc.
      2021   Phase 2   NCT04937530   Germany;
Raclopride   
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan;
Radiopharmaceuticals   
   University of California, Berkeley
      2019   Early Phase 1   NCT03926702   United States;
Rasagilin   
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany;
Rasagiline   
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany;
Riluzole   
   King's College London
      2000   Phase 3   NCT00211224   United Kingdom;
Rivastigmine   
   Assistance Publique Hopitaux De Marseille
      2016   Phase 3   NCT02839642   France;
   University Hospital Tuebingen
      2008   Phase 2   NCT00522015   Germany;
Salsalate   
   Adam Boxer
      2015   Phase 1   NCT02422485   United States;
Single dose C2N-8E12   
   C2N Diagnostics
      2015   Phase 1   NCT02494024   United States;
Stem cell therapy   
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2012   Phase 1/Phase 2   NCT01824121   Italy;
Sugar pill   
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany;
Suvorexant   
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States;
TPI 287 2 mg/m2   
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 20 mg/m2   
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPI-287 6.3 mg/m2   
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States;
TPN-101, 100 mg/day   
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
TPN-101, 200 mg/day   
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
TPN-101, 400 mg/day   
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States;
Tideglusib   
   Noscira SA
      2009   -   NCT01049399   Germany;Spain;United Kingdom;United States;
Trihexyphenidyl   
   1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital
      2019   -   JPRN-UMIN000036522   Japan;
UCB0107 (bepranemab)   
   UCB Biopharma SRL
      2020   Phase 1   NCT04658199   Belgium;Germany;Spain;United Kingdom;
Ubidecarenon   
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany;
Valproic acid   
   Nantes University Hospital
      2006   Phase 2   NCT00385710   France;
Vizamyl (flutemetamol(F-18))   
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
Water   
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Xeomin   
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Zoledronic Acid 5Mg/Bag 100Ml Inj   
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States;
Zolpidem   
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States;
[18F] APN-1607   
   Invicro
      2021   Phase 1   NCT05005819   United States;
[18F]-PI2620   
   Life Molecular Imaging GmbH
      2022   Phase 1   NCT05187546   Germany;
      2020   Phase 1   NCT04715750   Germany;
[18F]Florbetapir   
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03080051   United States;
      2016   Early Phase 1   NCT03058965   United States;
[18F]MNI-815 (MNI-815)   
   Molecular NeuroImaging
      2015   Phase 0   NCT02531360   United States;
[18F]MNI-952   
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03080051   United States;
[18F]MNI-958   
   Invicro
      2018   Phase 1   NCT03545789   United States;
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03058965   United States;
[18F]T807 ([18F]MNI-777)   
   Molecular NeuroImaging
      2014   Phase 1   NCT02103894   United States;
[F18]-FDDNP   
   Fundacion Clinic per a la Recerca Biomédica
      2013   Phase 0   NCT02214862   Spain;